CXCR4 and diabetic neuropathy: Our study shows that the release of HMGB1 might be involved in the activation of JNK pathways and blocking the release of HMGB1 by GLC may impede pain through alterations in CXCR4 mediated pain pathways, which could be an advantageous therapeutic approach for diabetic neuropathy.